It is with deep sadness that we announce our dear friend and colleague Torsten Goesch passed away unexpectedly earlier this week. Torsten was a highly respected member of the Rosetta team and he is much missed. Our thoughts and condolences go out to Torsten's family during this difficult time.
Biotech
Paratek Pharmaceuticals develops and commercialises antibiotic products. Paratek’s NUZYRA® is an FDA-approved tetracycline-class antibiotic designed to address a significant unmet need for adult patients with CABP and ABSSSI caused by susceptible bacteria. Gurnet Point Capital and Novo Holdings acquired Paratek for $462 million in 2023.
Location
USA
History
Gurnet Point Capital and Novo Holdings acquired Paratek for $462 million in 2023
Registered in England No. 3941653 | VAT No. GB 765 3567 96
© 2017 Rosetta Capital Limited | Authorised and regulated by the Financial Conduct Authority
